Cognicise Training for Seniors for Healthy Aging
NCT07098533, Not applicable, Completed, Poznan University of Physical Education
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Cognicise Training for Seniors for Healthy Aging | ClinicalTrials.gov |
| NCT number | NCT07098533 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 70 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Poznan University of Physical Education | ClinicalTrials.gov |
| Conditions | Depressive Symptom, Cognitive Functions, Quality of Life, Physical Fitness, Blood Biomarkers, Elderly (People Aged 65 or More), Postural Stability, Fall Risk, Postmenopausal Women, Cardiopulmonary | ClinicalTrials.gov |
| Interventions | Cognicise Training, Yoga Training | ClinicalTrials.gov |
| First posted | 2025-08-01 | ClinicalTrials.gov |
| Last updated | 2025-08-01 | ClinicalTrials.gov |
Registered outcomes 47
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Maximal Oxygen Uptake (VO₂max) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Predicted VO₂max estimated using a modified Åstrand-Ryhming protocol on a cycle ergometer. Higher values indicate better cardiovascular fitness. Units: milliliters per kilogram per minute (mL/kg/min) | ClinicalTrials.gov |
| Primary | Geriatric Depression Scale (GDS) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | GDS-15 (15 items). Scores range from 0 to 15; higher scores indicate more severe depressive symptoms. Units: score (0-15; higher = worse outcome) | ClinicalTrials.gov |
| Primary | Brain-Derived Neurotrophic Factor (BDNF) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Serum concentration of BDNF measured in fasting blood samples collected in the morning. Units: ng/mL. | ClinicalTrials.gov |
| Secondary | Rosenberg Self-Esteem Scale | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Stroop test10-item scale. Scores range from 0 to 30; higher scores indicate greater self-esteem. Units: score (0-30; higher = better outcome). | ClinicalTrials.gov |
| Secondary | Beck Depression Inventory (BDI-II) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | 21-item inventory. Scores range from 0 to 63; higher scores indicate greater depressive symptoms. Units: score (0-63; higher = worse outcome). | ClinicalTrials.gov |
| Secondary | Stroop Test - Completion Time | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Time (in seconds) to complete the interference condition of the Stroop Test. Lower values indicate better executive functioning. Units: seconds (s). | ClinicalTrials.gov |
| Secondary | Stroop Test - Number of Errors | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Number of errors during the interference condition. Lower scores indicate better cognitive control. Units: count. | ClinicalTrials.gov |
| Secondary | Body Mass Index (BMI) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Calculated as body mass (kg) divided by height (m) squared. Units: kg/m². | ClinicalTrials.gov |
| Secondary | Fat Mass | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Body fat percentage measured using bioimpedance analysis. Units: %. | ClinicalTrials.gov |
| Secondary | Muscle Mass | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Skeletal muscle mass percentage via bioimpedance analysis. Units: %. | ClinicalTrials.gov |
| Secondary | Visceral Fat | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Visceral fat level assessed via bioimpedance analysis, expressed as an index score. Units: score. | ClinicalTrials.gov |
| Secondary | Chest Expansion | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Thoracic expansion measured with tape during maximum inspiration and expiration. Units: centimeters (cm). | ClinicalTrials.gov |
| Secondary | Vital Capacity - Percentage of Predicted | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Vital capacity expressed as a percentage of predicted value based on age, sex, and height. Units: %. | ClinicalTrials.gov |
| Secondary | Minute Ventilation (VE) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Volume of air exhaled per minute. Units: liters per minute (L/min). | ClinicalTrials.gov |
| Secondary | Tidal Volume (TV) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Volume of air exhaled in one breath. Units: milliliters (mL). | ClinicalTrials.gov |
| Secondary | Respiratory Rate (RR) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Number of breaths per minute during resting conditions. Units: breaths per minute (brpm). | ClinicalTrials.gov |
| Secondary | FEV1/FVC Ratio | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Ratio of forced expiratory volume in one second to forced vital capacity. Units: percentage (%). | ClinicalTrials.gov |
| Secondary | Maximal Expiratory Flow (MEF75, MEF50, MEF25) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Maximal flow at selected points of forced expiration, expressed as a percentage of predicted. Units: percentage (%). | ClinicalTrials.gov |
| Secondary | Heart Rate (HR) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Measured at rest using standard heart rate monitor. Units: beats per minute (bpm). | ClinicalTrials.gov |
| Secondary | Systolic Blood Pressure (SBP) | Baseline (within 3 days before intervention) and Post-intervention (within 3 days after the 8-week program) | Measured in mmHg using standard sphygmomanometer. Units: millimeters of mercury (mmHg). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)